Dr Elena Nikiphorou

Consultant Rheumatologist
Dr elena_nikiphorou

Dr Elena Nikiphorou is a Consultant Rheumatologist and a Honorary Senior Lecturer at Kings College London with a clinical/academic interest in rheumatoid arthritis and spondyloarthritis. She has expertise in all aspects of general rheumatology, including connective tissue and metabolic bone disease; crystal (e.g. gout) and reactive arthritis.



Dr Elena Nikiphorou has a clinical and academic interest in inflammatory arthritis (IA). She completed her MBBS at University College London, also obtaining a First-Class Honours for her Intercalated BSc in Physiology, a British Pharmacological Society Award and a Wellcome Trust Vacation Scholarship for her BSc Research.

Following a number of diverse medical rotations in London as a junior doctor, she completed her rheumatology training at Addenbrooke’s Hospital, Cambridge. During this time, she was awarded a CLRN Research Associate Fellowship which culminated in her MD research at University College London, examining structural outcomes in Rheumatoid Arthritis (RA).

She is currently a Consultant Rheumatologist at King’s College Hospital and an Honorary Senior Lecturer at King’s College London. 

She has been the recipient of multiple awards, bursaries and competitive roles, including the Richard Kovacs prize by the Royal Society of Medicine in 2014, which supported a fellowship in Chicago and the Doris Hillier Award by the British Medical Association in 2018, to support her work on multimorbidity in rheumatoid arthritis and the development of management algorithms according to individual need.

At international level, she has been the recipient of several international bursaries and awards, including a European League Against Rheumatism (EULAR)-funded educational training fellowship in Finland and an Assessment of SpondyloArthritis international Society (ASAS) award in collaboration with Leiden University, The Netherlands. 

Dr Nikiphorou is involved in a number of national and international rheumatology societies and initiatives and has held a number of leadership positions including the Presidentship of the Rheumatology & Rehabilitation Section at The Royal Society of Medicine and the Chair of the largest network of young rheumatologists and researchers in Europe (EMEUNET- The EMErging EULAR [European League Against Rheumatism] NETwork).

More information

  • Consultant Rheumatologist
    King's College Hospital
  • Honorary Senior Lecturer
    King's College London

  • Lecturer

  • Year qualified 2004
  • University College London 1998 - 2004

  • 2019 John Glyn award, Royal College of Physicians 
  • 2019 Highly commended for the Oxford Handbook of Rheumatology 4th edition at the BMA Medical Book Awards
  • 2018 Doris Hillier award, British Medical Association
  • 2017 ASAS Research Grant Award 2017 
  • 2017 ACR-EULAR Exchange Programme 2017, San Diego 
  • 2015 EULAR Scientific Training Bursary-Finland 
  • 2014 Richard Kovacs prize: Fellowship (Chicago/Boston), Royal Society of Medicine, UK
  • 2014 European Society for Clinical and Economic aspects of Osteoporosis & Osteoarthritis (ESCEO) Eli Lilly Scholarship 
  • 2013 Academic Representative of British Rheumatologists in Training (BRiTs)

New thinking needed on methotrexate and ILD

The limbic


A team of UK rheumatologists has urged clinicians to not delay treatment with methotrexate in rheumatoid arthritis because of fears over lung injury.

Obesity Linked to Lower Remission, Higher Disability in Rheumatoid Arthritis Patients

American College of Rheumatology


Patients with rheumatoid arthritis whose body-mass index scores are higher have lower rates of remission and higher rates of disability, and effective weight screening and management should be a central feature of RA management.

Predictors of RA-Related Joint Surgery Analyzed

Clinical Pain Advisor


Patients with moderate disease activity who are taking conventional disease-modifying antirheumatic drugs (DMARD) have a similar risk of joint surgery as those with high disease activity

Patients with moderate RA as likely to need joint surgery as those with high disease



Patients with Rheumatoid Arthritis taking conventional DMARD therapy who have moderate disease activity have a similar risk of joint failure that requires surgery as those with high disease activity.

Remission vs low disease activity: function, quality of life and structural outcomes in the Early Rheumatoid Arthritis Study and Network

Authors: Nikiphorou E, Norton SJ, Carpenter L, Walsh DA, Creamer P, Dixey J, Young A, Kiely PDW

Year: 2019

Published by: Rheumatology (Oxford)

Treat to Target in Axial Spondyloarthritis

Authors: Nikiphorou E, Baraliakos X

Year: 2019

Published by: Rheum Dis Clin North Am

Methotrexate and interstitial lung disease: controversies and questions. A narrative review of the literature

Authors: Fragoulis GE, Conway R, Nikiphorou E.

Year: 2019

Published by: Rheumatology (Oxford)

Music, dancing.


Contact us

Request an appointment with our world-leading consultants today, or speak to our helpful advisors for tailored advice.